Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral... see more

Recent & Breaking News (NDAQ:AMLX)

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 11, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 11, 2024

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Berman

Accesswire March 11, 2024

Contact Levi & Korsinsky by April 9, 2024 Deadline to Join Class Action Against Amylyx Pharmaceuticals, Inc.(AMLX)

Accesswire March 11, 2024

Contact Levi & Korsinsky by April 9, 2024 Deadline to Join Class Action Against Amylyx Pharmaceuticals, Inc. (AMLX)

Accesswire March 11, 2024

AMLX LAWSUIT ALERT: Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire March 11, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 11, 2024

Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

PR Newswire March 11, 2024

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire March 11, 2024

Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire March 11, 2024

AMLX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 11, 2024

Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) should contact Levi & Korsinsky about pending Class Action - AMLX

Accesswire March 10, 2024

Investors who lost money on Amylyx Pharmaceuticals, Inc.(AMLX) should contact Levi & Korsinsky about pending Class Action - AMLX

Accesswire March 10, 2024

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 10, 2024

Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Accesswire March 10, 2024

Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

Accesswire March 10, 2024

Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 9, 2024

Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) should contact Levi & Korsinsky about pending Class Action - AMLX

Accesswire March 9, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX

Accesswire March 9, 2024

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 9, 2024